Streetbeat News

Products Services

IQV

IQVIA and CEPI have partnered to enhance global research preparedness for vaccines and other biological countermeasures against emerging infectious diseases. CEPI will utilize IQVIA's clinical research expertise and innovative solutions to strengthen pandemic preparedness in Low- and Middle-Income Countries (LMICs) and accelerate vaccine development.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:38 am

COEP

Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer cells. This builds upon the original agreement for SNAP-CAR T-Cell, a platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:37 am

PHIO

Phio Pharmaceuticals has announced the presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference. The data shows that melanoma cells treated with PH-894 become more recognizable to immune cells, increasing their potential for elimination. Additionally, PH-894 has demonstrated effectiveness as an antitumor cytotoxic agent.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:36 am

FCN

FTI Consulting has announced the launch of FTI Delta, an expansion of its strategy consulting business. The new initiative aims to provide clients with data-driven insights to drive business transformation.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:35 am

TSLA

GLJ Research CEO Gordon Johnson, a known Tesla bear, has shared stories of three Tesla owners who do not plan to buy another Tesla. The reasons cited include concerns about pricing, depreciation, and issues with certain hardware components and autonomous capabilities. However, these accounts have been met with skepticism by some, who accuse Johnson of fabricating the interviews or selectively choosing narratives that fit his bearish stance on Tesla.

Portfolio Pulse from Anan Ashraf

October 11, 2023 | 11:22 am

HMC

MSBHF

Honda Motor and Mitsubishi Corp are planning to collaborate on electricity infrastructure using electric vehicles (EVs), according to a report by Nikkei cited by Reuters.

Portfolio Pulse from Charles Gross

October 11, 2023 | 11:10 am

ZVSA

ZyVersa Therapeutics has announced a peer-reviewed publication in Nature Reviews Nephrology that substantiates the rationale for VAR 200's role in mediating the transport of cholesterol and lipids out of kidney cells to attenuate the progression of kidney disease.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:10 am

GOCO

GoHealth has launched PlanFit CheckUp, a tool designed to simplify the process of shopping for Medicare Advantage plans. The tool uses data analytics to recommend the most suitable plans based on individual needs.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:04 am

BMY

Cellares has announced that Bristol Myers Squibb (BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy. This is part of the Cellares Technology Adoption Partnership Program, where Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:04 am

TLSA

Tiziana Life Sciences (TLSA) has announced the presentation of six-month safety and biomarker data for its intranasal Foralumab in patients with non-active secondary progressive multiple sclerosis at the ECTRIMS Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:02 am